Jordan Medical Device Definition and Scope: Three-Part Structure with Six Intended Purposes

1. Key takeaways

Jordan’s definition of a medical device aligns closely with the European Union and the IMDRF framework, adopting a three-part structure of the device itself, six intended purposes, and an exclusion by mode of action. In GRZAN’s market access assessments, the first step is always to apply these three parts to the product in question.

The core wording of the definition reads as follows: any instrument, apparatus, material, tool, article, reagent or laboratory calibrator, whether used alone or in combination, including the software necessary for its proper use, prepared by the manufacturer specifically for use in humans, intended to achieve any of the purposes listed below, and whose principal intended action is not achieved by pharmacological, immunological or metabolic means (although it may be assisted in its function by such means).

The six intended purposes are: diagnosis, prevention, monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment, alleviation of or compensation for injury or disability; investigation, replacement or modification of anatomy or a physiological process; control of conception; sterilisation of medical devices, surfaces and surgical instrument sets; and provision of medical or diagnostic information by examining samples derived from the human body in vitro.

The third conclusion is that software is expressly written into the definition. The phrase “including the software necessary for its proper use” brings both stand-alone software and embedded or driving software within JFDA’s regulatory scope.

The definition operates as the gateway for every product question in Jordan. Before classification, before route design and before dossier compilation, the three-part test decides whether the product is a device at all. Applying it early, in writing, prevents the most expensive kind of mistake: discovering at review that the product was presented under the wrong regulatory identity and must be refiled through a different channel.

2. Legal basis

The definition and its boundaries rest on the following instruments.

Provision numbers are subject to the Arabic original texts issued in the Jordanian Official Gazette and by JFDA.

3. Expert insights

Insight 1: the mode-of-action clause is the watershed for drug-device demarcation. The exclusionary formulation in the definition — a principal intended action not achieved by pharmacological, immunological or metabolic means, although possibly assisted by them — matches the logic of Article 2 of the EU MDR. When GRZAN classifies drug-eluting or biologically material-bearing devices, it requires the manufacturer to first produce a statement of the principal mechanism of action, and only then decides whether the device channel or the drug-device combination channel applies, because the documentary lists for the two channels differ enormously. The same product presented with different mechanism statements can land in different regimes, so the statement must be drafted once, carefully, and then used consistently across the entire dossier.

Insight 2: the in vitro examination purpose expressly brings IVDs into scope. The sixth intended purpose (providing medical or diagnostic information by examining human samples in vitro) places IVDs under the same regulatory origin as devices, but IVDs have their own independent classification system and registration requirements, and their classification rules cannot be mixed with those for devices. A company that treats the IVD line as a mere annex to its device portfolio risks submitting a file that answers the wrong classification questions; the IVD dossier should be built from the start against its own rules.

Insight 3: sterilisation stands as a purpose in its own right. The fourth and fifth intended purposes list “control of conception” and “sterilisation of medical devices, surfaces and surgical instrument sets” separately. The latter is the direct legal basis on which sterilants, detergents and sterilisation equipment enter the device regulatory channel, and it explains why Jordan wrote sterilizers and detergents into the very title of its importation directives. Where a product combines cleansing for skin with disinfection for instruments, the purposes pull in different directions, and the correct channel must be confirmed in writing rather than assumed.

4. Practical recommendations

• Produce a written product demarcation statement. It should cover intended use, mechanism of action, presence of medicinal or biological materials, and the presence of software components, and it should serve as the starting point for later classification and route design.
• Seek advance consultation for boundary products. Drug-containing devices, devices with animal-derived materials and devices with nanomaterials may each trigger additional requirements in Jordan; confirm in writing with JFDA through the AR before submission.
• Do not omit software components from the dossier. Software delivered with a device, and stand-alone medical software, should both be reflected in the dossier; otherwise they will be requested during technical review.
• Keep the demarcation statement under version control and update it whenever the intended use, composition or software configuration changes.

5. Verification checklist

• □ Apply the three-part definition item by item to confirm the product falls within the device category
• □ State in writing the product’s principal mechanism of action and judge whether it is a drug-device combination
• □ Confirm whether software components exist and whether they must be listed separately
• □ Confirm whether animal-derived ingredients are present and whether TSE/BSE requirements are triggered
• □ Confirm whether the product is an IVD and whether the independent classification rules apply
• □ Attach the demarcation statement to the front section of the dossier so that reviewers encounter the mechanism rationale before any classification claim
• □ Re-verify the cited provision numbers against the Arabic original texts of the Official Gazette

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages Jordan Food and Drug Administration (JFDA) registrations, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com